Novo Nordisk A/S (NYSE:NVO) Shares Sold by Bard Financial Services Inc.

Bard Financial Services Inc. decreased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,765 shares of the company's stock after selling 3,625 shares during the quarter. Bard Financial Services Inc.'s holdings in Novo Nordisk A/S were worth $5,678,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Bank of America Corp DE increased its stake in shares of Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after buying an additional 1,165,955 shares during the last quarter. GQG Partners LLC increased its position in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Folketrygdfondet lifted its position in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after purchasing an additional 40,313 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Novo Nordisk A/S by 1.5% in the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock worth $715,084,000 after purchasing an additional 123,681 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $1.84 on Thursday, hitting $80.57. The stock had a trading volume of 6,851,395 shares, compared to its average volume of 6,978,414. The company's 50-day moving average is $66.58 and its two-hundred day moving average is $80.16. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The stock has a market cap of $361.56 billion, a price-to-earnings ratio of 24.49, a P/E/G ratio of 0.90 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on NVO. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Friday, June 6th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.